Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight Therapeutics Reports First Quarter 2020 Results

GlobeNewswire June 26, 2020

Knight Therapeutics Inc. announces voting results from the Annual Meeting

GlobeNewswire June 25, 2020

Notice of Knight Therapeutics' First Quarter 2020 Results Conference Call

GlobeNewswire June 18, 2020

Knight Therapeutics Inc. Announces Further Update on Extension of First Quarter 2020 Filings due to COVID-19

GlobeNewswire May 29, 2020

Knight to Present at the Jefferies 2020 Virtual Global Healthcare Conference

GlobeNewswire May 27, 2020

Knight Therapeutics Inc. Announces Extension of First Quarter 2020 Filings due to COVID-19

GlobeNewswire April 30, 2020

Knight Announces the Re-Launch of Trelstar® in Canada

GlobeNewswire April 20, 2020

Knight Therapeutics Announces Approval of IBSRELA(TM) in Canada

GlobeNewswire April 17, 2020

Knight Therapeutics Inc. Announces Triumvira Loan Repayment

GlobeNewswire April 16, 2020

Knight Therapeutics Inc. Announces Completion of its Normal Course Issuer Bid

GlobeNewswire April 15, 2020

Knight Therapeutics Files Annual Information Form

GlobeNewswire April 9, 2020

Knight Therapeutics Reports Fourth Quarter and Year End 2019 Results

GlobeNewswire March 30, 2020

Notice of Knight Therapeutics' Fourth Quarter 2019 Results Conference Call and update due to COVID-19 pandemic

GlobeNewswire March 27, 2020

Knight Announces Closing of Separation Agreement

GlobeNewswire March 16, 2020

Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight's PROBUPHINE® to their provincial drug plans in the fight against the opioid crisis

GlobeNewswire February 11, 2020

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

GlobeNewswire January 8, 2020

Knight Partners With Debiopharm for the Commercialization of Trelstar® in Canada

PR Newswire January 8, 2020

Knight to Present at the J.P. Morgan Healthcare Conference in San Francisco

GlobeNewswire January 7, 2020

Knight Therapeutics Announces Submission to B3 S.A. For Unified Tender Offer

GlobeNewswire December 20, 2019

Knight Therapeutics Announces Closing of Previously Announced Acquisition of Grupo Biotoscana

GlobeNewswire November 29, 2019